The Rationale for Potential Pharmacotherapy of COVID-19
On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread...
Main Authors: | Maha Saber-Ayad, Mohamed A. Saleh, Eman Abu-Gharbieh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/5/96 |
Similar Items
-
COVID-19: An Update about the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-05-01) -
COVID-19: A Brief Overview of the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-04-01) -
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
by: Megan Neary, et al.
Published: (2024-11-01) -
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
by: Eduardo Gallardo-Toledo, et al.
Published: (2023-10-01) -
Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
by: Victoria Gil Martínez, et al.
Published: (2021-07-01)